| Prev Close | 82.77 |
| Day Low/High | 80.38 / 82.74 |
| 52 Wk Low/High | 71.84 / 96.79 |
| Avg Volume | 1.51M |
Incyte Corp. (INCY)
80.89
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 216.78M |
| Market Cap | 17.94B |
| EPS | 2.10 |
| P/E Ratio | 40.38 |
| Div & Yield | N.A. (N.A) |
6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Trading Apple and Netflix, Beyond Meat Earnings: Market Recon
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
These two firms have successful drugs and could make nice additions for larger companies.
5 Attractive Ways to Invest in Oncology
Experts offer their top stock ideas in oncology detection and treatment.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Interesting Statistics
Some interesting statistics on the day: * Bitcoin is trading at $8.240, for a gain of nearly three percent today. * CNN's Fear and Greed Indicator stands at a neutral 49. * Gold is -$17.70, a drop of -1.4%. * Lumber is -$10, a -2.3% decline. * 3M ...
Who Benefits From Tax Reform?
Technology and biotech companies seem to be among the big winners.
Geron Shares Rise on Fast Track Designation -- Biotech Movers
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
MacroGenics Soars on Collaboration with Incyte -- Biotech Movers
MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.
These Stocks Have Changed Direction
Finding bullish and bearish reversals in the market.
Cramer: There Should Be More Takeovers Where These Came From
Buying's good for the acquirers, which should give other companies ideas.
Cramer: Let Loose the Growth Hounds
Day 2 of the selloff brings in an entirely new kind of buyer.
Closing Bell: Stocks End Higher As Corporate Earnings Take Focus
Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.
Takeaways and Observations (3PM Edition)
I started the day with an important piece on bonds - at least I hope so. Sell 'em, short 'em! Trade of the Week - long TBT (consistent with above). Well off the opening, at $37.60 now - and that's a good thing. So far, so good. At 230PM yield...
Stocks That Are Changing Direction
These charts are showing bullish or bearish reversals.
Cramer: Have Faith in International Strength
Because there are other things that will take the wind out of your sails.
Here Is Why Jim Cramer Is Bullish on Incyte
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Incyte INCY shares.
The Good, the Bad and the Ugly (Mid-Afternoon Edition)
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as its vacation time at the Kass household and I want to take a swim with my fam...
Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments
'These companies are all assessing the Trump effect,' Cramer said.
Jim Cramer Discusses Syria Missile Strikes, Jobs Report, Oil and Comcast's Mobile Service
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer reacts to the Syria missile strikes and the weaker-than-expected March jobs report.
Cramer: Retail Rally Shows the Perils of Being Too Negative
There's a forest fire in the sector.
Takeaways and Observations: Second Quarter Start
"I would say that (today) the averages are faring better than the average stock -- on average. If you know what I mean!" -- Kass Diary, Consider this Yogiism! With opening day yesterday and tonite's NCAA final (I like North Carolina in a high sin...
Cramer: Stay the Course, but Keep Cash Handy
It's pretty normal to have profit-taking after such a strong first quarter.
